Difference between revisions of "Alvocidib (Flavopiridol)"
Jump to navigation
Jump to search
m |
m (→Also known as) |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 29: | Line 29: | ||
===References=== | ===References=== | ||
| − | # '''JHOC-J1101:''' Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. [http://www.haematologica.org/content/100/9/1172 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800702/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26022709 PubMed] | + | # '''JHOC-J1101:''' Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. [http://www.haematologica.org/content/100/9/1172 link to original article] '''contains dosing details in manuscript''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800702/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/26022709/ PubMed] |
===[[Chronic lymphocytic leukemia]]=== | ===[[Chronic lymphocytic leukemia]]=== | ||
| Line 35: | Line 35: | ||
==Also known as== | ==Also known as== | ||
*'''Generic name:''' flavopiridol | *'''Generic name:''' flavopiridol | ||
| − | *'''Code names:''' HMR 1275, L-868275 | + | *'''Code names:''' HMR-1275, L-868275 |
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 43: | Line 43: | ||
[[Category:Acute myeloid leukemia medications (investigational)]] | [[Category:Acute myeloid leukemia medications (investigational)]] | ||
[[Category:Chronic lymphocytic leukemia medications (investigational)]] | [[Category:Chronic lymphocytic leukemia medications (investigational)]] | ||
| − | |||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Revision as of 02:06, 11 August 2023
Mechanism of action
From the NCI Drug Dictionary: A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis.
Route: PO
Preliminary data
Acute myeloid leukemia
FLAM
FLAM: FLavopiridol (Alvocidib), Ara-C (Cytarabine), Mitoxantrone
Regimen
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Zeidner et al. 2015 (JHOC-J1101) | Randomized Phase 2 (E) | 7+3d, high-dose dauno | Superior CR rate |
Chemotherapy
- Alvocidib (Flavopiridol) 50 mg/m2 IV once per day on days 1 to 3
- Cytarabine (Ara-C) 667 mg/m2/day IV continuous infusion on days 6 to 8 (total dose: 2000 mg/m2)
- Mitoxantrone (Novantrone) 40 mg/m2 IV once on day 9
One course
References
- JHOC-J1101: Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. link to original article contains dosing details in manuscript link to PMC article PubMed
Chronic lymphocytic leukemia
Also known as
- Generic name: flavopiridol
- Code names: HMR-1275, L-868275